Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age45+
SponsorGlaukos Corporation
About this trial
This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone
Eligibility criteria
Qualifiers
Cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye.
OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)
Disqualifiers
Active corneal inflammation or edema.
Retinal disorders not associated with glaucoma.
Trial design
Treatments tested in this trial
- iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery
- Sham procedure in conjunction with cataract surgery
Treatment groups
132 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov